Preview

Рецепт

Расширенный поиск

Нейросенсорная тугоухость в период пандемии COVID-19: что мы знаем сегодня?

https://doi.org/10.34883/PI.2021.24.3.007

Полный текст:

Аннотация

Нейросенсорную тугоухость (НСТ) необходимо выделить как одно из клинических проявлений COVID-19. Прямой нейротропный эффект SARS-CoV-2, воспалительная реакция, цитокиновый шторм, цереброваскулярные нарушения, прием ототоксических препаратов, широко используемых в качестве лечения во время пандемии, могут способствовать возникновению внезапной НСТ при COVID-19. Выявление SARS-CoV-2 как этиологического фактора внезапной НСТ является основанием для выбора правильной стратегии лечения с целью максимального клинического выздоровления и сведения к минимуму побочных эффектов и осложнений.

Традиционное использование глюкокортикостероидов в лечении НСТ при COVID-19 может представлять риск увеличения тяжести инфекции и вызывать задержку выведения вируса. Использование альтернативных методов лечения у пациентов с внезапной НСТ в случаях с COVID-19 может предотвратить такие нежелательные последствия. Применение кавинтона патогенетически обосновано при внезапной НСТ, обусловленной SARS-CoV-2, ввиду основных его эффектов. Кавинтон является нейропротектором, антиоксидантом, улучшает реологические свойства крови и микроциркуляцию, обладает антитромботическим действием, подавляет индукцию провоспалительных цитокинов (фактор некроза опухоли α, интерлейкин-1β и макрофагальный белок воспаления), тормозит индукцию воспалительных медиаторов в гладкомышечных клетках сосудов, эндотелии, макрофагах и эпителии, уменьшает гиперплазию неоинтимы и пролиферацию гладкой мускулатуры сосудов.

Об авторе

Е. И. Саливончик
Гомельский государственный медицинский университет
Беларусь

Гомель



Список литературы

1. (2008) Otorinolaringologiya: nacional’noe rukovodstvo [Otorhinolaryngology: national guide]. Pod red. V.T. Palchuna. M.: GEOTAR-Media, 960 p. (in Russian)

2. Levina M.A. (2015) Etiopatogeneticheskie aspekty sensonevral’noj tugouhosti [Etiopathogenetic aspects of sensorineural hearing loss]. Vestnik otorinolaringologii, 80(6), pp.77–81. https://doi.org/10.17116/otorino201580677-81.

3. Abdulkerimov H.T., Tavartkiladze G.A., Cygankova E.R., Boboshko M.Yu., Klimancev S.A. (2014) Sensonevral’naya tugouhost’: klinicheskie rekomendacii Nacional’noj medicinskoj associacii otorinolaringologov MZ RF [Sensorineural hearing loss: clinical recommendations of the National medical association of otorhinolaryngologists of the MH of RF]. Moskva-Sankt-Peterburg, 21 p. (in Russian)

4. Klinicheskij protokol “Diagnostika i lechenie pacientov s otorinolaringologicheskimi zabolevaniyami (vzrosloe naselenie)” v ambulatornyh usloviyah [Clinical protocol “Diagnostics and treatment of patients with otorhinolaryngological diseases (adult population)” in outpatient conditions] [01.06.2017 №49].

5. Vremennye metodicheskie rekomendacii “Profilaktik, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19)” [Temporary guidelines “Prevention, diagnostics, and treatment of the new coronavirus infection (COVID-19)”]. MZ RF, Versiya 10 (08.02.2021)

6. Rekomendacii (vremennye) ob organizacii okazaniya medicinskoj pomoshchi pacientam s infekciej COVID-19 [Temporary recommendations on organization of medical care for patients with COVID-19] (Prikaz MZ RB 11.11.2020 №1195).

7. Sriwijitalai W., Wiwanitkit V. (2020) Hearing loss and COVID-19: A note. Am J Otolaryngol., vol.2. doi:10.1016/j.amjoto.2020.102473.

8. Kalcioglu M.T. (2020) Can COVID-19 cause sudden sensorineural hearing loss? Int J InfectDis. Dec., vol.101(205). doi: 10.1016/j.ijid.2020.09.1468.

9. Luca P.D., Cassandro A., Scarpa P.D. (2020) Sudden sensorineural hearing loss and COVID-19. Int J Infect Dis. Dec., vol. 101, pp. 201–202. doi: 10.1016/j.ijid.2020.09.1467.

10. Dajhes N.A, Karneeva O.V., Machalov A.S., Kuznecov A.O., Sapozhnikov Ya.M., Balakina A.V., Hulugurova L.N., Karpov V.L. (2020) Audiologicheskij profil’ pacientov pri zabolevanii, vyzvannom virusom SARS-CoV-2. Vestnik otorinolaringologii, vol.85(5), pp.6–11. https://doi.org/10.17116/otorino2020850516.

11. Saniasiaya J. (2020) Hearing Loss in SARS-CoV-2: What Do We Know? J. Saniasiaya. Ear Nose Throat J. Aug 5: doi: 10.1177/0145561320946902

12. Koumpa F.S., Forde C.T., Manjaly J.G. (2020) Sudden irreversible hearing loss post COVID-19. BMJ Case Rep.; 13(11). doi: 10.1136/bcr-2020-238419.

13. Soldatov I.B. (1990) Lekcii po otorinolaringologii [Lectures on otorhinolaryngology]. M.: Medicina, 287 p. (in Russian)

14. Conlin A.E., Lorne S.P. (2007) Treatment of Sudden Sensorineural Hearing Loss: I. A Systematic Review. Arch Otolaryngol Head Neck Surg.; 133, 6, pp.573–581. doi: 10.1001/archotol.133.6.573.

15. Ivanec I.V. (2001) Vnezapnaya nejrosensornaya tugouhost’: prichiny vozniknoveniya i osobennosti techeniya [Sudden sensorineural hearing loss: causes and features of treatment]. Vestnik otorinolar, no 5, pp.15.

16. Foden N., Mehta N., Joseph T. (2013) Sudden onset hearing loss – causes, investigations and management. AustFam Physician; 42, 9, pp.641–644.

17. Preobrazhenskij H.A. (1980) Vnezapnaya gluhota. Sovremennoe sostoyanie problem [Sudden hearing loss. Modern state of the problem]. Vestn. Otorinolaringologii, no 6, pp.3–10.

18. Zagoryanskaya M.E., Rumyanceva M.G. (1995) Epidemiologicheskie aspekty narusheniya sluha u vzroslyh [Epidemiological aspects of hearing disorders in adults]. XV Vseros. s”ezd Ros.otorinolar.: Tez. dokl. M., 80 p.

19. Linthicum F.H. Jr., Doherty J., Berliner K.I. (2013) Idiopathic Sudden Sensorineural Hearing Loss: Vascular or Viral? Otolaryngol Head Neck Surg.

20. Ioseliani D.G., Rishko N.V., Filatov A.A., Koval’ A.N. (1988) Sostoyanie koronarnyh arterij i vozmozhnosti vypolneniya na nih rekonstruktivnyh operacij u bol’nyh s vpervye voznikshej stenokardiej [State of coronary arteries and possibility of reconstructive surgeries on them in patients with first-onset angina]. Kardiologiya, no 9, pp 43–46.

21. GarcíaBerrocal J.R., Ramirez-Camacho R., Portero F., Varga J.A. (2000) Role of viral and mycoplasma pneumoniae infection in idiopathic sudden sensorineural hearing loss. ActaOtolaryngologica., 120, 7, pp.835–839. doi: 10.1080/000164800750061688.

22. Mustafa M.W.M. (2020) Audiological profile of asymptomatic Covid-19 PCR-positive cases. Am J. Otolaryngol. May-June; 41(3). doi: 10.1016/j.amjoto.2020.102483.

23. Samir Abdel R. (2020) COVID-19 and sudden sensorineural hearing loss, a case report. Otolaryngology Case Reports., September, vol.16.

24. Kilic O., Tayyar Kalcioglu M., Cag Y., Tuysuz O., Pektas E., Caskurlu H., Cetın F. (2020) Could sudden sensorineural hearing loss be the sole manifestation of COVID-19? An investigation into SARS-COV-2 in the etiology of sudden sensorineural hearing loss. Int J Infect Dis., Aug., 97, pp. 208–211. doi: 10.1016/j.ijid.2020.06.023.

25. Antoniv V.F., Dajnyak L.B., Soldatov I.B. (1994) Rukovodstvo po otorinolaringologii [Guide to otorhinolaryngology]. M.: Medicina, pp.48–84.

26. Panova B., Rusev Yu. (2000) Lechenie ostroj poteri sluha i shuma v ushah preparatom mil’gamma (rastvor dlya in”ekcij i mil’gamma drazhe) [Treatment of acute hearing loss and tinnitus with the drug milgamma (solution for injection and pills)]. Forum-medikus, no 25, pp.20–23.

27. Palchun V.T., Kryukov A.I. (2001) Otorinolaringologiya. Rukovodstvo dlya vrachej [Otorhinolaryngology. Guide for physicians]. M.: Medicina, pp. 61–66. (in Russian)

28. Kunelskaya N.L., Polyakova T.S. (2006) Nejrosensornaya tugouhost’. Principy lecheniya [Sensorineural hearing loss. Principles of treatment]. Vestn. otorinolar [Prilozhenie], no 5, pp.161–163.

29. Friedland D.R., Cederberg C., Tarima S. (2009) Audiometric pattern as a predictor of cardiovascular status: Development of a model for assessment of risk. Laryngoscope, 119, 3, pp.473–486. doi: 10.1002/lary.20130.

30. Nikulina G.M., Rymsha M.A. (2005) Prognosticheskoe znachenie funkcii sluha na fone ishemicheskogo insul’ta [Prognostic significance of hearing function on the background of ischemic stroke]. Vestnik otorinolaringologii, vol.4, pp.9–11.

31. Kamchatnov P.R., Chugunov A.V., Umarova H.Ya. (2005) Vertebrobazilyarnaya nedostatochnost’ – voprosy diagnostiki i lecheniya [Vertebrobasilar insufficiency – issues of diagnostics and treatment]. Consilium Medicum, 7, 2.

32. Shidlovskij A.Yu. (2012) Vremennye pokazateli korotkolatentnyh sluhovyh vyzvannyh potencialov u bol’nyh s sensonevral’noj tugouhost’yu pri shejnom osteohondroze [Time indices of short-latency auditory evoked potentials in patients with sensorineural hearing loss in cervical osteochondrosis]. A.Yu. Shidlovskij. Rossijskaya Otorinolaringologiya, 3, pp.183–187.

33. Handazhapova Yu.A., Soldatenko M.V. (2006) Diagnostika i lechenie nejrosensornoj tugouhosti na fone narushenij krovotoka v pozvonochnyh arteriyah [Diagnostics and treatment of sensorineural hearing loss on the background of blood circulation disorders in vertebral arteries]. Rossijskaya Otorinolaringologiya, 1, pp.169–172.

34. Kunelskaya N.L., Kamchatnov P.R., Gulieva A.E. (2008) Lechebnaya taktika pri kohleovestibulyarnyh narusheniyah na fone discirkulyatornoj encefalopatii [Treatment tactics in cochleovestibular disorders on the background of dyscirculatory encephalopathy]. Vestnik Otorinolaringologii, 1, pp.47–50.

35. Charachon R., Moreno-Ribes V., Cordonnier D. (1978) Deafness due to renal failure. Clinicopathological study. Ann. Otolryngol. Chir. Cervicofac., 95, 3, pp.179–183.

36. Shiraiwa T., Kaneto H., Miyatsuka T., Kato K., Yamamoto K., Kawashima A., Kanda T., Suzuki M., Imano E., Matsuhisa M., Hori M., Yamasaki Y. (2005) Postprandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. BiochemBiophys Res Commun., 336, 1, pp.339–345. doi: 10.1016/j.bbrc.2005.08.158.

37. Alizade I.T. (2007) Narushenie sluhovoj funkcii i mikrocirkulyacii u bol’nyh saharnym diabetom [Hearing function and microcirculation disorder in patients with diabetes mellitus]. Vestnik otorinolaringologii, 1, pp.11–13.

38. Palchun V.T., Kunelskaya N.L., Sergeeva N.A., Bogdanec S.A. (2005) Osobennosti narusheniya lipidnogo obmena u pacientov s ostroj nejrosensornoj tugouhost’yu razlichnogo geneza [Features of violation of lipid metabolism in patients with acute sensorineural hearing loss of various genesis]. Vestnik otorinolaringologii, 4, pp.33–36.

39. Sagit M., Kavugudurmaz M., Guler S., Somdas M.A. (2013) Impact of mean platelet volume on the occurrence and severity of sudden sensorineural hearing loss. J Laryngol Otol., pp.1–5.

40. Abdulkerimov, H.T., Kartashova K.I. (2011) Sostoyanie svertyvayushchej sistemy krovi u pacientov s sensonevral’noj tugouhost’yu [State of the blood coagulation system in patients with sensorineural hearing loss]. Materialy XVIII s”ezda otorinolaringologov Rossii. SPb., 2, 3–7.

41. Zhou Y. Case report on early diagnosis of COVID-19. Disaster Medicine and Public Health Preparedness, 1–8. https://doi.org/10.1017/dmp.2020.6616

42. Chen N. (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, vol.395(10223), pp.507–513. https://doi.org.10.1016/S0140-6736(20)30211-7.

43. Luigi Angelo Vaira, Jerome R Lechien, MohamadKhalife, MarziaPetrocelli, Stephane Hans, Lea Distinguin, Giovanni Salzano, Marco Cucurullo, PieroDoneddu, Francesco Antonio Salzano, Federico Biglioli, FabriceJourne, Andrea FaustoPiana, Giacomo De Riu, Sven Saussez (2021) Psychophysical Evaluation of the Olfactory Function: European Multicenter Study on 774 COVID-19 Patients. Pathogens. Jan 12, 10 (1), pp.62. doi: 10.3390/pathogens10010062.

44. Wan Y., Shang J., Graham R., Baric R.S., Li. F. (2020) Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virology. (published online Jan 29). doi: 10.1128/JVI.00127-20.

45. (2020) Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19). United States, February 12–March 16. MMWR Morb Mortal Wkly Rep. 2020 Mar 18. 69.

46. Bernstein L., McGinley L., Sun L.H. (2020) Northern California coronavirus patient wasn’t tested for days. The Washington Post. Available at https://www.washingtonpost.com/health/northern-californian-tests-positive-for-coronavirus-in-first-us-case-with-no-link-to-foreign-travel/2020/02/26/b2088840-58fb11ea-9000-f3cffee23036_story.html. February 27. Accessed: February 27, 2020.

47. (2020) U.S. reports its first case of person-to-person transmission. The New York Times. Available at: https://www.nytimes.com/2020/01/30/world/asia/coronavirus-china.html#link-69c13d84. January 30. Accessed: January 30, 2020.

48. Li X.C., Zhang J, Zhuo J.L. (2017) The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res., 125, pp.21–38.

49. Korovin A.E., Novickij A.A., Makarov D.A. (2018) Ostryj respiratornyj distress-sindrom. Sovremennoe sostoyanie problemy [Acute respiratory distresssyndrome. Modern state of the problem]. Klinicheskaya patofiziologiya, vol.24, no 2, pp.32–41.

50. (2020) Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Available at http://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. February, pp.16–24, 2020; Accessed: March 04.

51. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, Mar 11.

52. Nicoletti B. (2020) Coding for Coronavirus: NEW Guidance Replaces the Rule of 1 Month. Ago-Medscape, Mar. 30. https://www.medscape.com.viewarticle/927633?nlid=134829.2049&src=WNL_mdplsnews_200403_mscpedit_imed&u=344220ST&spon=18&impID=2334280&faf=1.52. https://meduniver.com/Medical/Microbiology/klinika_covid19.htmlMedUniver.

53. Guan W.J., Ni Z.Y., Hu Y. (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. Feb 28.

54. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. (2020) Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. Feb 7.

55. Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S. (2020) Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med., Mar 13.

56. Lovato A., de Filippis C. (2020) Clinical Presentation of COVID-19: A systematic review focusing on upper airway symptoms. Ear Nose Throat J., pp. 1–8, https://doi.org/10.1177/014556132092076.

57. Cure E., Cure M.C. (2020) Comment on “Hearing loss and COVID-19: A note”. Am J Otolaryngol. July-August; 41(4). doi: 10.1016/j.amjoto.2020.102513.

58. Lopotko A.I. (2008) Prakticheskoe rukovodstvo po surdologii [Practical guide to audiology]. SPb.: Dialog, 274 p. (in Russian)

59. Iwasaki S., Tamagawa Y., Ocho S., Hoshino T., Kitamura K. (2000) Hereditary sensorineural hearing loss of unknown cause involving mitochondrial DNA 1555 mutation. ORL J OtorhinolaryngolRelat Spec., 62, 2, pp.100–103. doi: 10.1159/000027725.

60. Degen C., Lenarz T., Willenborg K. (2020) Acute Profound Sensorineural Hearing Loss After COVID-19 Pneumonia. Mayo Clin Proc. Aug; 95(8), pp.1801–1803. doi: 10.1016/j.mayocp.2020.05.034.

61. Karimi-Galougahi M., Safavi Naeini A., Raad N., Mikaniki N., Ghorbani J. (2020) Vertigo and hearing loss during the COVID-19 pandemic – is there an association? ActaOtorhinolaryngol Ital. Dec; 40(6), pp.463–465. doi: 10.14639/0392-100X-N0820

62. Jeon K.I., Xu X., Aizawa T., Lim J.H., Jono H., Kwon D.S., Abe J., Berk B.C., Li J.D., Yan C. (2010) Vinpocetine inhibits NF-κB-dependent inflammation via an ikkdependent but pde-independent mechanism. ProcNatlAcadSci USA, 107, pp.9795–9800. doi: 10.1073/pnas.0914414107.

63. Medina A.E. (2011) Therapeutic utility of phosphodiesterase type I inhibitors in neurological condition. Frontiers in NEUROSCIENCE, February, vol.5, Article 21.

64. Malyavina U.S., Ovchinnikov Yu.M., Fisenko V.P. (2003) Kavinton – sredstvo profilaktiki aminoglikozidnojsensonevral’noj tugouhosti u bol’nyh s razlichnymi formami tuberkuleznogo processa [Cavinton – a preventive measure for aminoglycoside sensorineural hearing loss in patients with various forms of tuberculosis process]. Vrach, no 4, pp.50–52.

65. Malyavina U.S., Ovchinnikov Yu.M., Fisenko V.P., Maliev B.M., Kalinina M.V., Dadasheva B.B. (2003) Opyt primeneniya preparata kavinton dlya predotvrashcheniya razvitiya nejrosensornoj tugouhosti u bol’nyh razlichnymi formami tuberkuleza [Experience of use of the drug Cavinton for prevention of sensorineural hearing loss in patients with various forms of tuberculosis]. Vestnik otorinolaringologii, no 3, pp. 35–40.

66. Malyavina U.S., Fisenko V.P., Ovchinnikov Yu.M. (2003) Lekarstvennaya profilaktika ototoksicheskogo dejstviya antibiotikov-aminoglikozidov [Drug prevention of ototoxic effect of antibiotics aminoglycosides]. Sb. tezisov 2-go s’ezda Rossijskogo obshchestva farmakologov. Ch. 2. M., pp.254.

67. Afonkin V.Yu. (2009) Sovremennaya skhema terapii Kavintonom. Novaya skhema primeneniya Kavintona v lechenii hronicheskoj nejrosensornoj tugouhosti [Modern scheme of therapy with Cavinton. New scheme of Cavinton use in treatment of chronic sensorineural hearing loss]. Vestnik otorilaringologii, no 5.


Для цитирования:


Саливончик Е.И. Нейросенсорная тугоухость в период пандемии COVID-19: что мы знаем сегодня? Рецепт. 2021;(3):377-388. https://doi.org/10.34883/PI.2021.24.3.007

For citation:


Salivonchyk E. Sensorineural Hearing Loss during the COVID-19 Pandemic: What do We Know Today? Recipe. 2021;(3):377-388. (In Russ.) https://doi.org/10.34883/PI.2021.24.3.007

Просмотров: 70


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1993-4882 (Print)
ISSN 2414-2263 (Online)